Literature DB >> 33238191

Probiotic nasal spray development by spray drying.

Katarina Jokicevic1, Shari Kiekens2, Eline Byl3, Ilke De Boeck4, Eline Cauwenberghs5, Sarah Lebeer6, Filip Kiekens7.   

Abstract

The upper respiratory tract (URT) is the main entrance point for many viral and bacterial pathogens, and URT infections are among the most common infections in the world. Recent evidences by our own group and others imply the importance of lactobacilli as gatekeepers of a healthy URT. However, the benefits of putting health-promoting microbes or potential probiotics, such as these URT lactobacilli, in function of URT disease control and prevention is underestimated, among others because of the absence of adequate formulation modalities. Therefore, this study entails important aspects in probiotic nasal spray development with a novel URT-derived probiotic strain by spray drying. We report quantitative and qualitative analysis of several spray-dried formulations, i.e. powders for reconstitution, based on disaccharide or sugar alcohol combinations with a polymer, including their long-term stability. Four formulations with the highest survival of >109 (Colony Forming Units) CFU/g after 28 weeks were further examined upon reconstitution which confirmed sufficiency of one bottle/dosage form during 7 days and rheological properties of shear-thinning. Tests also demonstrated maintained viability and cell morphology overall upon spraying through a nasal spray bottle in all 4 formulations. Lastly, application suitability in terms of high adherence to Calu-3 cells and antimicrobial activity against common URT pathogens was demonstrated and was not impacted neither by powder production process nor by spraying of reconstituted powder through a nasal spray device.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adhesion; Antimicrobial activity; Lacticaseibacillus; Nasal spray; Shelf-life; Spray drying

Year:  2020        PMID: 33238191     DOI: 10.1016/j.ejpb.2020.11.008

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

Review 1.  Insights on the Critical Parameters Affecting the Probiotic Viability During Stabilization Process and Formulation Development.

Authors:  Sharda Gurram; Durgesh K Jha; Devanshi S Shah; Madhuri M Kshirsagar; Purnima D Amin
Journal:  AAPS PharmSciTech       Date:  2021-05-18       Impact factor: 3.246

Review 2.  Antibiotic Resistance Crisis: An Update on Antagonistic Interactions between Probiotics and Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Basavaprabhu H Nataraj; Rashmi H Mallappa
Journal:  Curr Microbiol       Date:  2021-04-21       Impact factor: 2.188

3.  Open source anaerobic and temperature-controlled in vitro model enabling real-time release studies with live bacteria.

Authors:  Juliane Fjelrad Christfort; Chrysillis Judy Magaard Polhaus; Pi Westi Bondegaard; Tien-Jen Chang; En Te Hwu; Line Hagner Nielsen; Kinga Zór; Anja Boisen
Journal:  HardwareX       Date:  2022-02-05

Review 4.  Current Trends in the Production of Probiotic Formulations.

Authors:  Jakub Kiepś; Radosław Dembczyński
Journal:  Foods       Date:  2022-08-04

Review 5.  Characteristics of Probiotic Preparations and Their Applications.

Authors:  Guangqiang Wang; Yunhui Chen; Yongjun Xia; Xin Song; Lianzhong Ai
Journal:  Foods       Date:  2022-08-16

Review 6.  Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?

Authors:  Giovanna Batoni; Giuseppantonio Maisetta; Esingül Kaya; Semih Esin
Journal:  Antibiotics (Basel)       Date:  2022-02-28

Review 7.  Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic.

Authors:  Nadezhda Ivanova; Yoana Sotirova; Georgi Gavrailov; Krastena Nikolova; Velichka Andonova
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.